All CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
University of California, San Diego Dan Kaufman Quest - Discovery Stage Research Projects Human iPSC-derived chimeric antigen receptor-expressing macrophages for cancer treatment $222,200
City of Hope, Beckman Research Institute Karen Aboody Therapeutic Translational Research Projects Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer $2,873,262
University of California, Los Angeles Yvonne Chen Therapeutic Translational Research Projects BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma $3,176,805
City of Hope, Beckman Research Institute Saul Priceman Clinical Trial Stage Projects A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases $9,015,149
University of California, Los Angeles Theodore Nowicki Clinical Trial Stage Projects Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors $4,693,839
Angiocrine Bioscience, Inc. Edward Kavalerchik Clinical Trial Stage Projects AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 $6,192,579
Stanford University Philip Beachy Quest - Discovery Stage Research Projects Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer $1,265,436
University of California, San Francisco Karin Gaensler Therapeutic Translational Research Projects Developing engineered autologous leukemia vaccines to target residual leukemic stem cells $4,171,728
Poseida Therapeutics, Inc. Devon Shedlock Late Stage Preclinical Projects Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer $3,992,090
University of California, San Francisco Hideho Okada Quest - Discovery Stage Research Projects Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas $900,000
City of Hope, Beckman Research Institute Saul Priceman Quest - Discovery Stage Research Projects Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer $1,381,104
University of California, Los Angeles Lili Yang Quest - Discovery Stage Research Projects Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer $1,404,000
City of Hope, Beckman Research Institute John Zaia Late Stage Preclinical Projects Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients $3,684,259
University of California, Los Angeles Steven Dubinett Clinical Trial Stage Projects A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC $10,955,315
Stanford University Crystal Mackall Clinical Trial Stage Projects Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies $11,034,982
Fate Therapeutics, Inc. Bob Valamehr Late Stage Preclinical Projects IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell $4,000,000
University of California, San Diego Tannishtha Reya Quest - Discovery Stage Research Projects Targeting Cancer Stem Cells in Hematologic Malignancies $1,960,560
University of California, San Diego Catriona Jamieson Therapeutic Translational Research Projects A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia $2,511,767
University of California, San Diego Dan Kaufman Therapeutic Translational Research Projects Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment $4,698,821
Human BioMolecular Research Institute John Cashman Inception - Discovery Stage Research Projects Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication $303,785
Loma Linda University Julia Unternaehrer-Hamm Inception - Discovery Stage Research Projects Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer $172,870
Loma Linda University David Baylink Inception - Discovery Stage Research Projects Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy $178,967
Children's Hospital of Los Angeles Michael Pulsipher Clinical Trial Stage Projects Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) $4,825,587
Poseida Therapeutics, Inc. Matthew Spear Clinical Trial Stage Projects Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma $19,813,407
Nohla Therapeutics Inc Colleen Delaney Clinical Trial Stage Projects A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML $4,310,000
City of Hope, Beckman Research Institute Christine Brown Clinical Trial Stage Projects Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma $12,753,854
Angiocrine Bioscience, Inc. Edward Kavalerchik Clinical Trial Stage Projects AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 $5,000,000
University of California, San Diego Thomas Kipps Clinical Trial Stage Projects A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers $18,292,674
University of California, San Diego Ezra Cohen Therapeutic Translational Research Projects Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies $5,795,584
University of California, Los Angeles Gay Crooks Quest - Discovery Stage Research Projects Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy $965,636
Cellerant Therapeutics, Inc. Swapna Panuganti Late Stage Preclinical Projects Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia $6,863,755
City of Hope, Beckman Research Institute Markus Müschen Quest - Discovery Stage Research Projects Lgr5-mediated self-renewal in B cell selection and leukemia-initiation $2,186,520
University of California, San Diego Yuan Chen Quest - Discovery Stage Research Projects A Novel Approach to Eradicate Cancer Stem Cells $279,977
City of Hope, Beckman Research Institute Yuan Chen Quest - Discovery Stage Research Projects A Novel Approach to Eradicate Cancer Stem Cells $1,539,935
University of California, San Diego Dan Kaufman Quest - Discovery Stage Research Projects Targeted off-the-shelf immunotherapy to treat refractory cancers $1,936,936
University of California, Los Angeles John Chute Quest - Discovery Stage Research Projects Protein tyrosine phosphatase - sigma inhibitors for hematopoietic regeneration $2,116,708
Stanford University Hiromitsu Nakauchi Quest - Discovery Stage Research Projects Novel Rejuvenated T Cell Immunotherapy for Lung Cancer $1,968,456
Stanford University Albert Wong Therapeutic Translational Research Projects 2nd Generation Vaccine for the Treatment of Glioblastoma $2,929,889
Stanford University Philip Beachy Inception - Discovery Stage Research Projects Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells $210,906
University of California, Berkeley Jacob Corn Inception - Discovery Stage Research Projects Genome editing for causation and reversion of MPN-associated mutations in human hematopoietic stem cells $235,800
University of California, Los Angeles Owen Witte Inception - Discovery Stage Research Projects Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer $209,160
University of California, Los Angeles Lili Yang Therapeutic Translational Research Projects Stem Cell-Based iNKT Cell Therapy for Cancer $6,956,775
Angiocrine Bioscience, Inc. Paul Finnegan Late Stage Preclinical Projects Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy $3,797,117
ImmunoCellular Therapeutics Anthony Gringeri Clinical Trial Stage Projects A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy $5,391,016
University of California, Davis Mehrdad Abedi Clinical Trial Stage Projects Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients $8,414,265
Caladrius Biosciences Robert Dillman Clinical Trial Stage Projects Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. $3,000,000
University of California, Los Angeles John Chute Research Leadership Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors $4,645,297
University of California, San Diego David Cheresh Basic Biology V CD61-driven stemness program in epithelial cancer $1,161,000
University of California, San Diego Thomas Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) $4,179,598
Stanford University Irving Weissman Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $6,505,568
University of California, Los Angeles Dennis Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors $5,683,693
University of California, Los Angeles Robert Reiter Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
University of California, San Francisco Ann Zovein New Faculty Physician Scientist Human endothelial reprogramming for hematopoietic stem cell therapy. $2,197,683
Stanford University Michelle Monje New Faculty Physician Scientist White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” $2,800,526
Stanford University Michael Cleary Basic Biology IV Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells $1,244,455
University of California, Los Angeles Owen Witte Basic Biology IV Trop2 dependent and independent mechanisms of self-renewal in human cancer stem cells $1,254,960
University of California, Los Angeles Antoni Ribas Disease Team Therapy Development - Research Genetic Re-programming of Stem Cells to Fight Cancer $14,144,221
City of Hope, Beckman Research Institute Stephen Forman Early Translational III Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,215,447
University of California, Los Angeles Antoni Ribas Disease Team Therapy Planning I Genetic Re-programming of Stem Cells to Fight Cancer $97,785
Stanford University Albert Wong Disease Team Therapy Planning I Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma $109,750
OncoMed Pharmaceuticals, Inc. Timothy Hoey Disease Team Therapy Planning I Anti-Notch1, OMP-52M51: A New Cancer Therapeutic to Reduce CSC Frequency $65,120
University of California, Davis Mehrdad Abedi Disease Team Therapy Planning I Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients $66,880
Gordon Research Conferences Catriona Jamieson Conference 2011 Gordon Conference on Stem Cells and Cancer $40,000
University of California, Los Angeles Noriyuki Kasahara Early Translational II Stem cell-based carriers for RCR vector delivery to glioblastoma $3,340,625
University of California, San Diego Catriona Jamieson Early Translational II Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy $3,103,041
University of California, San Francisco Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
Children's Hospital of Los Angeles Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $850,769
Sanford Burnham Prebys Medical Discovery Institute Robert Wechsler-Reya Research Leadership The role of neural stem cells in cerebellar development, regeneration and tumorigenesis $5,226,049
University of California, San Diego Dennis Carson Disease Team Research I Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) $19,999,826
City of Hope, Beckman Research Institute Karen Aboody Disease Team Research I Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials $17,890,623
University of California, Los Angeles Dennis Slamon Disease Team Research I Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors $19,979,660
Stanford University Irving Weissman Disease Team Research I Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells $18,759,276
University of California, San Francisco Mitchel Berger Disease Team Research I Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) $6,214,914
University of California, Los Angeles Antoni Ribas New Faculty II Stem Cells for Immune System Regeneration to Fight Cancer $3,072,000
University of California, Los Angeles Brigitte Gomperts New Faculty II Stem Cells in Lung Cancer $2,381,572
University of California, San Diego Catriona Jamieson New Faculty II Derivation and Characterization of Myeloproliferative Disorder Stem Cells from Human ES Cells $3,065,572
University of California, San Francisco Emmanuelle Passegue New Faculty II Mechanisms Underlying the Responses of Normal and Cancer Stem Cells to Environmental and Therapeutic Insults $2,124,488
University of California, Los Angeles Zack Jerome New Cell Lines Generation of clinical grade human iPS cells $1,341,000
City of Hope, Beckman Research Institute Michael Barish Disease Team Planning Genetically-modified neural stem cells for treatment of high-grade glioma $55,000
University of California, Los Angeles Siavash Kurdistani New Faculty I Epigenetics in cancer stem cell initiation and clinical outcome prediction $3,063,450
University of California, Los Angeles Hanna Mikkola New Faculty I Mechanisms of Hematopoietic stem cell Specification and Self-Renewal $2,286,900
University of California, Davis Chong-Xian Pan New Faculty I Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells $2,386,409
University of California, San Diego Yang Xu Comprehensive Grant Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells $2,467,200
University of Southern California Peter Laird SEED Grant Screening for Oncogenic Epigenetic Alterations in Human ES Cells $647,431
Gladstone Institutes, J. David Warner Greene SEED Grant The APOBEC3 Gene Family as Guardians of Genome Stability in Human Embryonic Stem Cells $717,363
University of California, Irvine Charles Limoli SEED Grant Using human embryonic stem cells to treat radiation-induced stem cell loss: Benefits vs cancer risk $593,242
Children's Hospital of Los Angeles Elizabeth Lawlor SEED Grant hESC as tools to investigate the neural crest origin of Ewing's sarcoma $595,576
Stanford University Julien Sage SEED Grant Functions of RB family proteins in human embryonic stem cells $498,609
University of California, Los Angeles Zoran Galic SEED Grant Genetic Enhancement of the Immune Response to Melanoma via hESC-derived T cells $616,800
City of Hope, Beckman Research Institute Timothy O'Connor SEED Grant Sources of Genetic Instability in Human Embryonic Stem Cells. $327,311
University of California, San Francisco Thea Tlsty SEED Grant Role of the tumor suppressor gene, p16INK4a, in regulating stem cell phenotypes in embryonic stem cells and human epithelial cells. $614,784
University of California, San Diego Catriona Jamieson SEED Grant Derivation and Characterization of Cancer Stem Cells from Human ES Cells $616,305
Icon for XLSX export